Vikram R Paralkar
Overview
Explore the profile of Vikram R Paralkar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
446
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Gimotty P, Matthews A, Mamtani R, Luger S, Hexner E, et al.
Blood Adv
. 2025 Jan;
9(3):533-544.
PMID: 39888631
Little is known about the impact of recent advances in acute myeloid leukemia (AML) treatment on racial/ethnic disparities in survival outcomes. We performed a retrospective cohort study of patients with...
2.
Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, et al.
Eur J Haematol
. 2024 Dec;
114(4):626-635.
PMID: 39726154
Venetoclax with hypomethylating agents (HMA) is the standard of care for acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy and is associated with tumor lysis syndrome (TLS). TLS...
3.
Pawar A, Somers P, Alex A, George S, Antony C, Verner R, et al.
bioRxiv
. 2024 Dec;
PMID: 39677666
Myeloid leukemias are heterogeneous cancers with diverse mutations, sometimes in genes with unclear roles and unknown functional partners. PHF6 and PHIP are two poorly-understood chromatin-binding proteins recurrently mutated in acute...
4.
Rondeau V, Berman J, Ling T, OBrien C, Culp-Hill R, Reisz J, et al.
Sci Transl Med
. 2024 Sep;
16(766):eadn1285.
PMID: 39321266
Acute myeloid leukemia (AML) is a devastating disease initiated and maintained by a rare subset of cells called leukemia stem cells (LSCs). LSCs are responsible for driving disease relapse, making...
5.
Jalnapurkar S, Pawar A, George S, Antony C, Somers P, Grana J, et al.
Leukemia
. 2024 Jul;
38(9):1938-1948.
PMID: 39004675
Acute myeloid leukemia is characterized by uncontrolled proliferation of self-renewing myeloid progenitors accompanied by a differentiation arrest. PHF6 is a chromatin-binding protein mutated in myeloid leukemias, and its isolated loss...
6.
Paralkar V
Curr Opin Hematol
. 2024 Apr;
31(4):199-206.
PMID: 38568093
Purpose Of Review: Ribosomal RNAs (rRNAs) are transcribed within nucleoli from rDNA repeats by RNA Polymerase I (Pol I). There is variation in rRNA transcription rates across the hematopoietic tree,...
7.
Jalnapurkar S, Pawar A, George S, Antony C, Grana J, Gurbuxani S, et al.
bioRxiv
. 2024 Jan;
PMID: 38260439
Acute myeloid leukemia is characterized by uncontrolled proliferation of self-renewing myeloid progenitors. PHF6 is a chromatin-binding protein mutated in myeloid leukemias, and its loss increases mouse HSC self-renewal without malignant...
8.
Antony C, Somers P, Gray E, Pimkin M, Paralkar V
STAR Protoc
. 2023 Jul;
4(3):102463.
PMID: 37481729
FISH-Flow (fluorescence in situ hybridization-flow cytometry) involves hybridizing fluorescent oligos to RNA and quantifying fluorescence at a single-cell level using flow cytometry. Here, we present a FISH-Flow protocol to quantify...
9.
Matthews A, Perl A, Luger S, Gill S, Lai C, Porter D, et al.
Am J Hematol
. 2023 Jun;
98(8):1254-1264.
PMID: 37334852
Intensive chemotherapy with cytarabine and anthracycline (7&3) remains the standard therapy for patients medically fit for induction, but the assessment of fitness remains controversial. Venetoclax and hypomethylating agent (ven/HMA) combination...
10.
George S, Pimkin M, Paralkar V
J Biol Chem
. 2023 Apr;
299(6):104766.
PMID: 37121547
rRNAs are transcribed from ribosomal DNA (rDNA) repeats, the most intensively transcribed loci in the genome. Due to their repetitive nature, there is a lack of genome assemblies suitable for...